Alpha lipoic acid (ALA) is a sulfur-containing compound your body makes in small amounts to power key energy-producing reactions inside mitochondria, and it doubles as a versatile antioxidant that works in both water and fat. As a supplement, it has accumulated a surprisingly wide evidence base: randomized trials in diabetic neuropathy, meta-analyses on inflammatory markers, animal studies on weight and brain health, and small clinical experiments on skin aging and blood-vessel function. The strongest clinical data supports its use for nerve pain in diabetes at a specific dose, but the compound touches enough metabolic pathways that researchers keep finding new angles to investigate.
What ALA Does Inside Your Cells
Your mitochondria synthesize lipoic acid on their own, using building blocks from fatty-acid metabolism and iron-sulfur clusters. Once made, it acts as a cofactor for several enzyme complexes that sit at the crossroads of energy production, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase.1PubMed Central. Lipoic acid metabolism and mitochondrial redox regulation Without these enzymes working properly, cells cannot efficiently convert food into usable energy. The amounts your body produces are tiny and tightly bound to those enzyme complexes, so supplemental ALA operates somewhat differently: it floods the bloodstream and tissues at concentrations far above what mitochondria make on their own, which is what drives the antioxidant and signaling effects people are actually interested in.
The Antioxidant That Recycles Other Antioxidants
Most antioxidants work in one compartment. Vitamin C is water-soluble; vitamin E is fat-soluble. ALA is amphiphilic, meaning it functions in both environments. When your body reduces ALA to its partner form, dihydrolipoic acid (DHLA), the pair can quench free radicals directly and chelate metals that would otherwise catalyze oxidative damage.2PubMed Central. Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits What makes the ALA/DHLA system unusual is that DHLA can regenerate other spent antioxidants, including vitamin E, vitamin C, and glutathione.3General Pharmacology: The Vascular System. The pharmacology of the antioxidant lipoic acid That recycling ability is why some researchers describe ALA as a “network antioxidant” rather than just another radical scavenger.
R-Form Versus S-Form
ALA has two mirror-image forms. The R-enantiomer is the one your body makes naturally; the S-enantiomer is a byproduct of chemical synthesis. Most supplements sell the racemic mixture (a 50/50 blend), though pure R-ALA products exist at a higher price point. The practical difference comes down to absorption: in healthy volunteers, the R-form had an absolute bioavailability of about 38%, compared with roughly 28% for the S-form from the same oral solution.4European Journal of Pharmaceutical Sciences. Enantioselective pharmacokinetics and bioavailability of different racemic α-lipoic acid formulations in healthy volunteers From solid tablets, those numbers drop to around 25% and 20%, respectively, but the R-form still leads. Both enantiomers absorb quickly, with peak blood levels typically arriving within about 20 to 30 minutes of taking a dose.5PubMed Central. Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms
When it comes to biological activity, the R-form also appears to have an edge. In a study on oxidative stress in laying hens, R-ALA outperformed S-ALA on several inflammatory and antioxidant markers.6PubMed Central. R- Is Superior to S-Form of α-Lipoic Acid in Anti-Inflammatory and Antioxidant Effects in Laying Hens The catch is that R-ALA supplements can be less stable, sometimes clumping or degrading unless properly formulated. For most people buying ALA off a shelf, the racemic version is the form that has been used in the vast majority of clinical trials, which makes it the best-documented option even if it is not theoretically optimal per milligram.
Diabetic Neuropathy and the 600 mg Dose
If ALA has a flagship clinical use, it is diabetic peripheral neuropathy. Germany has approved intravenous ALA for this condition for decades, and the oral evidence has matured substantially. A meta-analysis pooling data from controlled trials found that intravenous ALA at 600 mg per day for three weeks produced a roughly 24% greater reduction in neuropathy symptoms (pain, burning, numbness) compared with placebo, with about 53% of ALA-treated patients qualifying as responders versus 37% on placebo.7PubMed. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis Improvements in objective nerve-function tests, such as pin-prick sensation and ankle reflexes, appeared alongside the symptom relief. The clinical consensus from trial data points to 600 mg daily as the sweet spot: higher doses have not consistently produced additional benefit, and lower doses may not be enough.8PubMed Central. Alpha-lipoic Acid and diabetic neuropathy
The improvement is not instant. In pooled analyses, a measurable separation from placebo started appearing after about eight days of treatment. People expecting overnight relief will be disappointed, but the trajectory is consistent: symptoms keep improving over weeks of continued use.
Blood Sugar and Insulin Sensitivity
ALA interacts with glucose metabolism through at least two pathways studied in lab and animal models. In muscle cells, it promotes the movement of glucose transporters to the cell surface through a signaling cascade that partly overlaps with insulin’s own pathway.9Diabetes. The Antihyperglycemic Drug α-Lipoic Acid Stimulates Glucose Uptake via Both GLUT4 Translocation and GLUT4 Activation Separately, ALA activates an energy-sensing enzyme called AMPK in skeletal muscle, which increases fat burning and reduces the fat buildup that interferes with insulin signaling. In obese rats, this translated into better whole-body insulin-stimulated glucose disposal.10PubMed. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle
Human evidence on blood sugar is scattered across small trials, many of them in people with type 2 diabetes or metabolic syndrome. The effects are generally modest, which is important context: ALA is not a substitute for diabetes medication. But for people already managing their blood sugar through diet, exercise, and medication, it may offer a small additional nudge in the right direction, particularly given that diabetic neuropathy and insulin resistance often coexist in the same patient.
Inflammation Markers
A systematic review and meta-analysis of randomized controlled trials found that ALA supplementation significantly lowered three major inflammatory markers in people with metabolic diseases: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α).11PubMed Central. The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders In a separate trial focused on hemodialysis patients, eight weeks of ALA supplementation reduced high-sensitivity CRP by about 19% compared with placebo.12PubMed. Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis The anti-inflammatory signal is fairly consistent across populations, which makes sense given ALA’s upstream effects on oxidative stress: less oxidative damage generally means less inflammatory signaling.
Weight Loss Potential
Animal research on ALA and body weight is striking. In rodents, ALA decreased food intake and ramped up energy expenditure by suppressing AMPK activity in the hypothalamus, the brain region that regulates appetite.13Nature Medicine. Anti-obesity effects of α-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase In aged mice, four weeks of ALA led to roughly a 16% loss of initial body weight, with reductions in both fat and lean mass.14PubMed Central. Alpha-lipoic acid increases energy expenditure by enhancing AMPK-PGC-1α signalling in the skeletal muscle of aged mice
Translating rodent weight-loss results to humans requires caution. The doses used relative to body weight in mice are far higher than typical human supplement doses. Human trials do exist and generally show modest weight loss, enough for a systematic review to describe ALA as a useful adjunct in obesity treatment at doses up to 1,200 mg per day.15PubMed. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials Nobody should expect dramatic results from ALA alone, but the direction of the effect is real and consistent enough that researchers keep investigating it.
Brain and Nerve Protection
ALA crosses the blood-brain barrier, which is a non-trivial quality for a supplement — many antioxidants cannot.16PubMed. α-Lipoic Acid, an Organosulfur Biomolecule a Novel Therapeutic Agent for Neurodegenerative Disorders Once in the central nervous system, it reduces oxidative damage and supports neurotransmitter levels, at least in laboratory models. In rats with induced strokes, pretreatment with ALA significantly shrank the infarct volume, reduced brain swelling, and improved neurological recovery, working through an antioxidant defense pathway called Nrf2/HO-1.17Cellular Physiology and Biochemistry. α-Lipoic Acid Promotes Neurological Recovery After Ischemic Stroke by Activating the Nrf2/HO-1 Pathway to Attenuate Oxidative Damage
The gap between animal neuroprotection data and proven human cognitive benefits remains wide. Researchers are interested in ALA for conditions like Alzheimer’s disease and multiple sclerosis, but large, definitive human trials are still thin on the ground. The blood-brain barrier penetration and the strong preclinical data make it a plausible candidate, though “plausible candidate” is not the same as “proven therapy.” People taking ALA hoping it will sharpen their thinking should keep expectations realistic.
Blood Vessel Function
Endothelial function — how well the inner lining of your blood vessels dilates in response to blood flow — is an early marker of cardiovascular health. A meta-analysis of five randomized trials including 300 participants found that ALA supplementation increased flow-mediated dilation (a standard measure of endothelial function) by an average of about 2.4 percentage points compared with controls, with the effect varying by age and health status.18PubMed. The effect of Alpha-lipoic acid supplementation on endothelial function: A systematic review and meta-analysis In one notable trial, patients with metabolic syndrome who received ALA for four weeks saw a 44% improvement in flow-mediated vasodilation compared with placebo, and combining ALA with the blood-pressure drug irbesartan pushed that to 75%.19PubMed. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome
A smaller trial in overweight and obese adolescents found that ALA increased baseline arterial diameter to levels comparable with healthy-weight peers, though the percentage change in dilation after a stimulus did not reach significance in that particular study.20PubMed Central. Effect of Alpha-Lipoic Acid Supplementation on Endothelial Function and Cardiovascular Risk Factors in Overweight/Obese Youths The vascular evidence is encouraging but early — these are small trials, and nobody has demonstrated that ALA reduces actual heart attacks or strokes.
Fatty Liver Disease
ALA’s combination of antioxidant, anti-inflammatory, and insulin-sensitizing properties makes it a natural candidate for fatty liver research, and recent animal work has been promising. In mice fed a high-fat diet, ALA treatment visibly reduced lipid accumulation in the liver, lowered triglyceride and cholesterol levels in liver tissue, and reduced the ballooning degeneration that signals liver-cell injury.21PubMed Central. α-Lipoic Acid Alleviates Non-Alcoholic Fatty Liver Disease by Elevating Chaperone-Mediated Autophagy and Increasing β-Oxidation via AMPK-TFEB Axis A 2025 review pulling together studies across different diet models — high-fat, high-fructose, choline-deficient, and diabetic models — concluded that ALA has consistent preventive effects on fatty liver disease through mechanisms spanning mitochondrial function, inflammation, and oxidative stress.22PubMed Central. Lipoic acid in metabolic dysfunction-associated steatotic liver disease: a review Human clinical trials specifically targeting fatty liver with ALA are still emerging, so this area should be filed under “watch this space.”
Skin Aging and Cosmetic Use
ALA has quietly entered the cosmeceutical world, mostly in topical creams rather than oral supplements. In a randomized, double-blind, split-face trial, a cream containing 5% ALA applied for 12 weeks reduced skin roughness by about 51% on the treated side compared with about 41% on the placebo side, measured by laser profilometry.23British Journal of Dermatology. Randomized, placebo‐controlled, double blind study on the clinical efficacy of a cream containing 5%α‐lipoic acid related to photoageing of facial skin Another single-blinded study using a cubosomal ALA gel formulation found that after six months, the treated side of the face showed significantly greater clinical improvement and increased epidermal thickness compared with placebo.24PubMed. Assessment of cubosomal alpha lipoic acid gel efficacy for the aging face Lab-on-a-chip models of human skin equivalents have confirmed that ALA boosts expression of structural proteins involved in skin barrier integrity, including filaggrin, involucrin, and collagen IV.25PubMed Central. Effect of α-Lipoic Acid on the Development of Human Skin Equivalents Using a Pumpless Skin-on-a-Chip Model These are small studies, and ALA creams are not going to replace retinoids or sunscreen for anti-aging. But the evidence is consistent enough that dermatology researchers consider it a legitimate active ingredient, not just marketing fluff.
Fertility and PCOS
Women with polycystic ovary syndrome (PCOS) undergoing fertility treatment have been a focus of recent ALA research. When ALA was combined with metformin (a common PCOS medication) in women going through assisted reproduction, the combination significantly increased the number of mature oocytes, fertilization rates, and good-quality embryos compared with metformin alone. Oxidative stress markers improved and insulin-related hormonal measures dropped.26Anatomy & Cell Biology. Combination of alpha lipoic acid and metformin supplement improve assisted reproductive technologies outcomes in polycystic ovary syndrome patients Pregnancy and live-birth rates, however, did not differ significantly between groups in that trial, suggesting ALA’s benefit may be more about improving the building blocks (egg and embryo quality) than guaranteeing a pregnancy.
A separate trial found that combining ALA with myo-inositol and cysteine led to more large follicles, more mature oocytes retrieved, better embryo quality, and a higher pregnancy rate in PCOS patients compared with those receiving only myo-inositol.27Japan Journal of Research. Effect of Myo-Inositol in Combination with Alpha-Lipoic Acid and Cysteine Based Co-Treatment on Oocyte Quality in Women with Polycystic Ovarian Syndrome Undergoing Assisted Reproductive Technology This is a young field with small sample sizes, but the early direction is interesting enough that fertility clinics are paying attention.
Chemotherapy-Induced Neuropathy — Mixed Results
Because ALA helps with diabetic nerve damage, researchers have tested whether it can also protect nerves from chemotherapy drugs like paclitaxel. The picture here is honestly mixed. One trial in breast cancer patients found that ALA significantly improved neuropathy scores after 9 and 12 weeks of paclitaxel treatment and lowered markers of inflammation and oxidative stress.28PubMed Central. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities But a separate randomized, double-blind trial found no significant difference between ALA and placebo for chemotherapy-induced neuropathy scores, pain, or functional outcomes.29PubMed Central. Oral Alpha-Lipoic Acid to Prevent Chemotherapy-Induced Peripheral Neuropathy The conflicting results may reflect differences in cancer type, chemotherapy regimen, ALA dose, or when supplementation started relative to treatment. For now, the evidence is too inconsistent to make a confident recommendation in this setting.
Practical Matters for Supplement Users
Bioavailability is a real constraint with oral ALA. Overall absorption from standard formulations sits around 30%, reduced by breakdown in the liver, poor solubility, and degradation in stomach acid.30PubMed Central. Insights on the Use of α-Lipoic Acid for Therapeutic Purposes Liquid formulations outperform tablets for peak plasma levels, and newer amphiphilic delivery systems aim to push absorption higher. Food slows and reduces ALA absorption, which is why labels typically say to take it on an empty stomach, ideally 30 minutes before a meal. One pharmacokinetic detail worth noting: women tend to absorb roughly 20 to 30% more ALA (by total exposure) than men at the same dose after adjusting for body weight, though peak concentrations are similar between the sexes.31PubMed Central. Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms
Safety Profile and Cautions
The safety data on ALA is reassuringly boring. A meta-analysis pooling 71 randomized placebo-controlled trials found that ALA supplementation was not associated with any increased risk of adverse events, and this held across subgroups including people with diabetes, cardiovascular disease, kidney impairment, neurological disorders, pregnant women, and children.32PubMed Central. Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies Most people tolerate doses up to 1,200 mg per day without significant problems.33PubMed. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials Mild gastrointestinal symptoms like nausea are the most commonly reported side effect at higher doses.
There is one rare but serious caution worth knowing about. In a small number of cases, ALA has triggered insulin autoimmune syndrome (Hirata disease), a condition in which the body produces antibodies against its own insulin, causing dangerous episodes of low blood sugar. Reported cases have been concentrated in individuals of Japanese descent carrying a particular immune-system gene variant (HLA-DRB1*0403).34PubMed. Possible relevance of HLA-DRB1*0403 haplotype in insulin autoimmune syndrome induced by alpha-lipoic acid, used as a dietary supplement This is exceedingly rare, but anyone who develops unexplained hypoglycemia while taking ALA should stop and talk to a doctor. People on insulin or sulfonylurea medications should also be aware that ALA can modestly lower blood sugar, creating the potential for additive effects.
Metal Chelation and Heavy Metal Claims
ALA and its reduced form DHLA have the chemical capacity to bind metals, and you will find health practitioners promoting ALA as a mercury detoxifier or a general “chelation” supplement. There is a kernel of truth here: both ALA and DHLA have been studied as potential scavengers of mercury and other heavy metals in toxicology research. However, the clinical evidence for using ALA as a standalone heavy-metal detoxification agent in humans is thin. Standard medical chelation therapy for heavy-metal poisoning uses purpose-built drugs with well-characterized dosing and safety data, not over-the-counter antioxidant supplements. If you have genuine heavy-metal exposure, ALA is not a substitute for medical treatment.
Where ALA’s chelating properties may matter more is in everyday cellular maintenance, binding stray iron and copper that would otherwise catalyze free-radical production. That background metal-scavenging activity is probably part of how ALA exerts its antioxidant effects, rather than something you need to specifically target.